FRI0250 SUBCLINICAL ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS: COMPARABLE EFFECT OF TRADITIONAL CARDIOVASCULAR RISK FACTORS WITH RHEUMATOID ARTHRITIS

Background Both rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients are associated with an increased and premature prevalence of atherosclerosis. This has been characteristically attributed to the inflammation present in both diseases Objectives To analyze the differences in the role of traditional cardiovascular risk factors in the subclinical atherosclerosis between the two diseases. Methods Cross-sectional study encompassing 602 subjects, 276 SLE and 326 RA patients. Carotid plaques were assessed by ultrasonography. A multivariable regression analysis was performed to evaluate if classic cardiovascular-related risk factors influence differentially on subclinical carotid atherosclerosis in SLE compared to RA patients. Results Traditional cardiovascular risk factors were found to be prevalent in RA and SLE patients. Age (interaction factor p=0.000), hypertension (interaction factor p=0.034), and diabetes (interaction factor p=0.037) were found to have a higher effect on cIMT in RA patients compared to SLE subjects. No differences between RA and SLE were discovered in the effect of traditional cardiovascular factors over the presence of carotid plaque when univariate interaction was performed. After final adjustment for demographics, the presence of others traditional cardiovascular factors, and disease related data, no differences were found in the influence of hypertension, diabetes, dyslipidemia or current smoking over cIMT or the presence of carotid plaque. Moreover, the effect of the addition of various cardiovascular risk factors on the subclinical carotid atherosclerosis did not differ between both diseases. Conclusion The influence of traditional cardiovascular risk factors (hypertension, diabetes, dyslipemia and smoking) over cIMT and carotid plaque is equal in RA and SLE. No interaction was found between traditional cardiovascular risk factors and disease related data in the effect of the former on subclinical atherosclerosis. Disclosure of Interests Hiurma Sanchez-Perez: None declared, Juan Carlos Quevedo-Abeledo: None declared, Inigo Rua-Figueroa: None declared, Beatriz Tejera-Segura: None declared, Vanessa Hernandez-Hernandez: None declared, Antonia de Vera-Gonzalez: None declared, Alejandra Delgado-Gonzalez: None declared, Raquel Lopez-Mejias: None declared, Soledad Ojeda Grant/research support from: AMGEN, Speakers bureau: AMGEN, Miguel A Gonzalez-Gay Grant/research support from: Prof. MA Gonzalez-Gay received grants/research supports from Abbvie, MSD, Jansen and Roche., Speakers bureau: Consultation fees/participation in company sponsored speaker’s bureau from Pfizer, Lilly, Sobi, Celgene, Novartis, Roche and Sanofi., Ivan Ferraz-Amaro: None declared